Unfortunately, Biogen Idec has announced that the experimental ALS drug has not shown efficacy in a large-scale trial; its development will be discontinued
Article Highlights:
Dexpramipexole, an experimental drug for amyotrophic lateral sclerosis (ALS), had shown encouraging results in a phase 2 trial but did not continue to show promise in a phase 3 trial.
Biogen Idec will discontinue its dexpramipexole development program; the company has provided phone numbers for people who want more information.
Biogen Idec will continue to pursue other ALS-related research.
To learn more, read the full ALS News Online article. here
No comments:
Post a Comment